



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Ralinepag

Item No. 30009

CAS Registry No.: 1187856-49-0
Formal Name: 2-[[*trans*-4-[[[(4-chlorophenyl)phenylamino]carbonyl]oxy]methyl]cyclohexyl]methoxy]-acetic acid
MF: C₂₃H₂₆ClNO₅
FW: 431.9
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Ralinepag is supplied as a solid. A stock solution may be made by dissolving the ralinepag in the solvent of choice, which should be purged with an inert gas. Ralinepag is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of ralinepag in these solvents is approximately 10 mg/ml in ethanol and DMSO and approximately 15 mg/ml in DMF.

Ralinepag is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, ralinepag should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Ralinepag has a solubility of approximately 0.11 mg/ml in a 1:8 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Ralinepag is a prostaglandin I₂ (PGI₂) receptor (IP) agonist (K_i = 3 nM).¹ It is selective for IP over the PGD₂ receptor (DP₁) and the PGE₂ receptor subtypes EP₁₋₄ (K_is = 2,600, 9,600, 611, 143, and 678 nM, respectively, in radioligand binding assays). Ralinepag induces cAMP accumulation in CHO-K1 cells expressing human recombinant IP (EC₅₀ = 8.5 nM). *In vivo*, ralinepag (30 mg/kg) prevents increases in pulmonary arterial pressure and vessel wall thickness in a rat model of monocrotaline-induced pulmonary arterial hypertension.

Reference

1. Tran, T.-A., Kramer, B., Shin, Y.-J., *et al.* Discovery of 2-(((1*r*,4*r*)-4-(((4-chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralingepag): An orally active prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. *J. Med. Chem.* **60**(3), 913-927 (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/26/2020

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM